Viveka Roychowdhury

The last month saw a major milestone in the patent versus patient debate

What does it take to transform bovine colostrum into a nutritional supplement, ensuring that all the immunoglobins, vitamins and…

According to the latest data from the India Brand Equity Foundation (IBEF), the Indian domestic pharma market ended FY15 with a…

Currently focused on skin, renal and lung cancer, the platform has potential to treat all types of cancer tumours as well as viral…

Some industry observers are surprised that ‘significant violations’ of this nature have not warranted an import alert or ban

The ‘no pain, no gain’ mantra seems to be finally putting the $25 billion AstraZeneca on the road to recovery, as it continues to…

After a decade of pain, there are some reassuring signs that the pharmaceutical industry may just be seeing the faint glimmers of…

With the launch of the Digital India campaign in early July, it is time to relook India Pharma Inc’s engagement with technology

Patients from 23 countries, including India, participated in the trial, which is reportedly the first prospective trial to…

With little known Lee Pharma filing India's third compulsory licensing (CL), legal eagles and everyone interested or connected to…